Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and PAVmed subsidiary, announced its upcoming presentation at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The presentation is scheduled for Thursday, November 21, 2024, at 1:30 p.m. ET.
Investors can access both live and replay webcasts through the company's investor relations website at ir.luciddx.com. The webcast recording will remain available for a minimum of 30 days following the event.
Lucid Diagnostics (Nasdaq: LUCD), una società di diagnostica medica per la prevenzione del cancro e filiale di PAVmed, ha annunciato la sua prossima presentazione al Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum a New York. La presentazione è programmata per giovedì 21 novembre 2024, alle 13:30 ET.
Gli investitori possono accedere sia alle trasmissioni in diretta che a quelle registrate tramite il sito web delle relazioni con gli investitori della società all'indirizzo ir.luciddx.com. La registrazione della trasmissione rimarrà disponibile per un minimo di 30 giorni dopo l'evento.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico para la prevención del cáncer y subsidiaria de PAVmed, anunció su próxima presentación en el Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum en Nueva York. La presentación está programada para el jueves 21 de noviembre de 2024, a la 1:30 p.m. ET.
Los inversores pueden acceder tanto a las transmisiones en vivo como a las grabaciones a través del sitio web de relaciones con los inversores de la empresa en ir.luciddx.com. La grabación de la transmisión estará disponible durante un mínimo de 30 días después del evento.
Lucid Diagnostics (Nasdaq: LUCD), 암 예방 의료 진단 회사이자 PAVmed의 자회사로, 뉴욕에서 열리는 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum에서의 발표를 알렸습니다. 발표는 2024년 11월 21일 목요일 오후 1시 30분 ET에 예정되어 있습니다.
투자자들은 회사의 투자자 관계 웹사이트인 ir.luciddx.com을 통해 실시간 및 재방송 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 이벤트 이후 최소 30일 동안 이용 가능합니다.
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostic médical pour la prévention du cancer et filiale de PAVmed, a annoncé sa prochaine présentation lors du Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum à New York. La présentation est prévue pour le jeudi 21 novembre 2024, à 13h30 ET.
Les investisseurs peuvent accéder à la fois aux webinaires en direct et aux rediffusions via le site web des relations avec les investisseurs de l'entreprise à l'adresse ir.luciddx.com. L'enregistrement du webinaire restera disponible pendant un minimum de 30 jours après l'événement.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen für medizinische Diagnostik zur Krebsprävention und Tochtergesellschaft von PAVmed, gab seine bevorstehende Präsentation beim Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York bekannt. Die Präsentation ist für Donnerstag, den 21. November 2024, um 13:30 Uhr ET angesetzt.
Investoren können sowohl Live- als auch Replay-Webcasts über die Investor-Relations-Website des Unternehmens unter ir.luciddx.com abrufen. Die Aufzeichnung des Webcasts bleibt mindestens 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
Live and replay webcasts may be accessed on the investor relations section of the Company's website at ir.luciddx.com. The webcast will be archived and available for replay for at least 30 days after the event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302308185.html
SOURCE Lucid Diagnostics
FAQ
When is Lucid Diagnostics (LUCD) presenting at the Canaccord Genuity Forum in 2024?
How can investors watch Lucid Diagnostics' (LUCD) Canaccord Genuity Forum presentation?
How long will the replay of Lucid Diagnostics' (LUCD) Canaccord presentation be available?
